Erratum: Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

被引：0

作者：

I Breitkreutz

M S Raab

S Vallet

T Hideshima

N Raje

C Mitsiades

D Chauhan

Y Okawa

N C Munshi

P G Richardson

K C Anderson

机构：

来源：

Leukemia | 2008年 / 22卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Correction to: Leukemia (2008) 22, 1925–1932; doi:10.1038/leu.2008.174; published online 3 July 2008 Owing to a typesetting error, Figure 2b of the above article was published incorrectly. The correct figure is reproduced here. The publisher apologizes for this error and any inconvenience it may have caused.

引用

页码：1973 / 1973

共 50 条

[31] Bone marrow of multiple myeloma patients provides an environment favoring osteoclastogenesis.
Huston, A
Lokshin, A
Anderson, G
Primeaux, S
Anderson, J
Callander, N
Roodman, GD
Lentzsch, S
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S236 - S236
[32] Modern markers for evaluating bone disease in multiple myeloma
Pop, Vlad
Parvu, Andrada
Craciun, Alexandra
Farcas, Anca Daniela
Tomoaia, Gheorghe
Bojan, Anca
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (05)
[33] Comparison of urinary markers for bone resorption in multiple myeloma
Houzé, P
Bellik, B
Brouet, JC
Bouro, F
Bousquet, B
CLINICA CHIMICA ACTA, 2000, 300 (1-2) : 181 - 193
[34] Survival of Patients with Multiple Myeloma That Is Refractory to Both Bortezomib and Lenalidomide: A Retrospective Study
Miyazaki, Kanji
Suzuki, Kenshi
BLOOD, 2018, 132
[35] Prognostic impact of bone turnover markers in multiple myeloma
Dizdar, O.
Barista, I.
Kalyoncu, U.
Karadag, O.
Celik, I.
Kars, A.
Hascelik, G.
Cila, A.
Pinar, A.
Tekuzman, G.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[36] Erratum: Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide
I N M Micallef
A D Ho
L M Klein
S Marulkar
P J Gandhi
G Calandra
P A McSweeney
Bone Marrow Transplantation, 2011, 46 : 1398 - 1398
[37] Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival-In Most
Mikhael, Joseph R.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3269 - +
[38] The Clinical Utility of Bone Resorption and Bone Formation Markers in Multiple Myeloma
Faraz, Shandabul
Pearse, Roger N.
Yadlapati, Sujitha
Jayabalan, David
Rossi, Adriana C.
Mark, Tomer M.
Niesvizky, Ruben
Lane, Joseph
BLOOD, 2015, 126 (23)
[39] Socioeconomic Factors and Survival of Multiple Myeloma Patients
Chamoun, Kamal
Firoozmand, Amin
Caimi, Paolo
Fu, Pingfu
Cao, Shufen
Otegbeye, Folashade
Metheny, Leland
Patel, Seema
Gerson, Stanton L.
Boughan, Kirsten
De Lima, Marcos
Malek, Ehsan
CANCERS, 2021, 13 (04) : 1 - 12
[40] CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma
Sanchez, Eric
Li, Mingjie
Li, Jennifer
Wang, Cathy
Chen, Haiming
Jones-Bolin, Susan
Hunter, Kathryn
Ruggeri, Bruce
Berenson, James R.
LEUKEMIA RESEARCH, 2012, 36 (11) : 1422 - 1427

← 1 2 3 4 5 →